| Description | Procarbazine is an antineoplastic chemotherapy drug for the treatment of Hodgkin's lymphoma and certain brain cancers. The drug is metabolized and activated in the liver. It also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine. |
| Synonyms | CB 400-497, NSC-77213, Ro 4-6467/1, Ro 4-6467, Procarbazine |
| molecular weight | 221.3 |
| Molecular formula | C12H19N3O |
| CAS | 671-16-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Soluble |
| References | 1. Revollo J, Bhalli JA, Tebbe C, Noteboom J, Thomas D, McKinzie P, Felton N, Pearce MG, Dobrovolsky VN. Spectrum of Pig-a mutations in T lymphocytes of rats treated with procarbazine. Mutagenesis. 2017 Dec 8. doi: 10.1093/mutage/gex032. [Epub ahead of print] PubMed PMID: 29237063. 2. Schiff D. Low-grade Gliomas. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1564-1579. doi: 10.1212/CON.0000000000000537. PubMed PMID: 29200111. 3. Nayak L, Reardon DA. High-grade Gliomas. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1548-1563. doi: 10.1212/CON.0000000000000554. PubMed PMID: 29200110. 4. Kobe C, Dietlein M, Hellwig D. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Semin Nucl Med. 2018 Jan;48(1):28-36. doi: 10.1053/j.semnuclmed.2017.09.003. Epub 2017 Sep 19. Review. PubMed PMID: 29195615. |